Influence of long-term volume therapy with hydroxyethyl starch on leukocytes in patients with acute stroke.
A repeated administration of hydroxyethyl starch affects hemostasiological and rheological factors such as the concentration of factor VIII/von Willebrand factor, platelet volume and plasma viscosity. An earlier study showed that HES also lowers the concentration of fibronectin, a molecule important in the reticuloendothelial system (RES). RES has a "clearing function" and is a part of the non-immune-specific defense mechanisms of the body. It is involved in the elimination of HES from the blood. Since leukocytes are another important part of the unspecific defense system, the goal of the present study was to investigate whether HES affects leukocytes. After giving their informed consent, 20 patients with cerebral perfusion disorders were randomized and underwent a double-blind 10-day hypervolemic hemodilution with HES 200/0.5/13 or HES 70/0.5/4. The numbers of leukocytes, percentage of lymphocytes, percentage of neutrophilic granulocytes and hemoglobin concentration were measured. The absolute number of leukocytes did not change significantly, but the share of neutrophilic granulocytes increased. The increase in neutrophilic granulocytes reflects an increase in phagocytic activity. HEs 200/0.5/13, which has the larger in vivo molecular weight (MW = 95 kD), caused a larger increase in neutrophilic granulocytes than HES 70/0.5/4, which has an in vivo MW of 58 kD.
Woessner
Ralph
R
Neurologische Klinik, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany.
Grauer
Markus T
MT
Dieterich
Hans-Jürgen
HJ
Treib
Wolfgang
W
Stoll
Martin
M
Treib
Johannes
J
D000208:Acute Disease; D004311:Double-Blind Method; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000009:adverse effects / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*
D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes